For those to whom the issue may seem cosmetic, roughly 52% of Peyronie's sufferers report erectile dysfunction and pain and are likely to really, really want the treatment. For Peyronie's, at least 130 patients a year fit the "30 - 90 degree curvature" criteria of the ideal patient, utilized in the IMPRESS trial. Stock reports and company profiles may be our best source of information about collengase (AA500). In the case of Dupuytren's, for which Xiaflex is already approved, 95%+ of patients are reimbursed under common insurance schemes. By being a shareholder I hope to get some insight regarding the results of their AA500 testing and testing results. Autolus Therapeutics plc (AUTL) Stock Price, News, Quote & History - Yahoo Finance AUTL - Autolus Therapeutics plc NasdaqGS - NasdaqGS Real Time Price. The total cost of treatment per patient is expected to be US$ 40,000, and there is no news yet on whether insurers are willing to cover the costs. The future of Xiaflex for this new indication is not yet certain. The firm noted the stock is down 30 since March, but Testim appears to have stabilized and Stendra is. ![]() Each treatment cycle consists of two Xiaflex injection procedures (in which Xiaflex is injected directly into the collagen-containing structure of the penis) and one penile modeling procedure performed by the health care professional." MKM Partners upgraded Auxilium Pharmaceuticals (AUXL) to 'buy' and set a 26 price target. According to the FDA, " treatment course for Peyronie’s disease consists of a maximum of four treatment cycles. Autolus Therapeutics plc (AUTL) Stock Price, News, Quote & History - Yahoo Finance AUTL - Autolus Therapeutics plc NasdaqGS - NasdaqGS Real Time Price.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |